Displaying 113 (all) recruiting clinical trials.
-
A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) and Pembrolizumab in Combination with Other Investigational Agents in Subjects with High-risk Non-muscle-Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy
This is a single arm, multi-site, open-label trial of pembrolizumab (MK-3475) in subjects with high risk non-muscle-invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette Guerin ... -
PHASE II: ADAPTIVE TREATMENT DE-ESCALATION IN FAVORABLE RISK HPV-POSITIVE OROPHARYNGEAL CARCINOMA
This will be a phase II single-arm clinical trial. The primary objective of this study is to evaluate progression-free survival at 2 years. The secondary ... -
A Phase 1 Open-Label Multicenter Study to Assess the Safety Tolerability and Immunogenicity of mRNA-4157 Alone or in Combination in Participants with Solid Tumors
This is a 2-part, open-label, Phase 1, multicenter dose-escalation, FIH study of mRNA-4157 monotherapy in subjects with resected solid tumors (Part A) who are in ... -
NMTRC014: NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)
High risk Neuroblastoma (HR NB) remains a challenge in pediatric oncology, accounting for 15% of all pediatric cancer deaths. While most patients are able to ... -
PNH Registry
Alexion Pharmaceuticals, Inc. has been the Sponsor of a global PNH Registry since August 2004 and enrolling patients with PNH worldwide. The primary aim of ... -
A Phase II open label study of IMMU-132 in metastatic urothelial cancer after failure of platinum-based regimen or anti-PD-1/ PD-L1 based immunotherapy
This is an international, multi-center, open-label, Phase II study in patients with metastatic urothelial cancer after failure of platinum-based regimen or anti-PD-1 / PD-L1 based immunotherapy ... -
A Phase 2 Randomized Study of Adjuvant Immunotherapy With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Versus Pembrolizumab Alone After Complete Resection of High-Risk Melanoma (mRNA-4157-P201)
This is an open-label, randomized, Phase 2 study. Approximately 150 eligible patients will be randomly assigned in a 2:1 ratio to the combination arm ... -
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation
Study 849-001 is a multi-center, Phase 1/2, multiple expansion cohort trial evaluating the safety, PK, metabolites, PD and clinical activity/efficacy of MRTX849 in ... -
Site for WUH: AGCT1532: Phase 3 Accelerated BEP Trial: A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours
Site for To determine if accelerated BEP (Bleomycin, Etoposide, cisPlatin) is superior to standard BEP as first-line chemotherapy for intermediate and poor-risk metastatic GCTs. -
ACNS1833: A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727 IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
Low-grade gliomas (LGG) are the most common central nervous system tumor among children, accounting for approximately one-third of pediatric brain tumors. These tumors include a ...